Identity and sequence
Eloralintide (LY3841136) is described as a selective, long-acting amylin receptor agonist peptide. A detailed primary amino-acid sequence was not confirmed in the sources used here, so no specific sequence is asserted.
Reported mechanism
The cited studies describe selective amylin-receptor pharmacology. This distinguishes the molecule from GLP-1 agonists and unimolecular incretin co-agonists; it does not imply that every amylin-family molecule or catalog formulation is interchangeable.
Primary literature
Bhattachar et al. (2026) report a phase 1 proof-of-concept study covering pharmacokinetics, tolerability and body-weight outcomes in human participants. Billings et al. (2025) report a 48-week randomized phase 2 study in participants with obesity. These are human clinical studies, not cell or rodent mechanistic experiments.
Limitations and prepared strengths
The 5 mg and 10 mg entries share molecule-family background. Clinical study materials and conditions do not establish the contents or outcomes of either prepared product. No sequence verification, human-use protocol or catalog efficacy claim follows from these references. This private article remains subject to review.
Related
- eloralintide 10mgproduct
- eloralintide 5mgproduct
References
- Bhattachar S et al. (2026). Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. [primary; human phase 1 proof-of-concept study]PMID: 41559929DOI: 10.1111/dom.70439
- Billings LK et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. [primary; human phase 2 randomized trial]PMID: 41207310DOI: 10.1016/S0140-6736(25)02155-5
More questions?
Ask our Support Team — they can answer follow-up questions about this topic, COAs, storage, or anything else in the research library.
Tap the "Chat with us" tab on the right edge of any page.